AKT isoform-specific expression and activation across cancer lineages

Jue Wang, Wei Zhao, Huifang Guo, Yong Fang, Sarah Elizabeth Stockman, Shanshan Bai, Patrick Kwok Shing Ng, Yang Li, Qinghua Yu, Yiling Lu, Kang Jin Jeong, Xiaohua Chen, Meng Gao, Jiyong Liang, Wentao Li, Xingsong Tian, Eric Jonasch, Gordon Mills, Zhiyong Ding

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Aberrant AKT activation is prevalent across human cancer lineages, providing an important therapeutic target. AKT comprises three isoforms that mediate critical non-redundant, even opposing functions in cancer pathophysiology. Therefore, targeting specific AKT isoforms in particular cancers may be more effective than pan-AKT inhibition while avoiding disadvantages of pan-AKT inhibition. Currently, AKT isoform-specific expression and activation in cancer are not clearly characterized. Methods: We systematically characterized AKT isoform-specific expression and activation in 211 cancer cell lines derived from different lineages and genetic backgrounds using a reverse-phase protein array platform. Results: We found that phosphorylation, but not expression, of AKT1 and AKT2 was coordinated in most but not all cells. Different cancer lineages displayed differential AKT1 and AKT2 expression and phosphorylation. A PIK3CA hotspot mutation H1047R but not E545K was associated with selective activation of AKT2 but not AKT1. Conclusions: Our study identified and validated AKT isoform-specific expression and phosphorylation in certain cell lines and demonstrated that genetic changes can affect AKT isoform-specific activation. These results provide a more precise understanding of AKT isoform-specific signaling and, in addition, facilitate AKT isoform targeting for personalized cancer therapies.

Original languageEnglish (US)
Article number742
JournalBMC Cancer
Volume18
Issue number1
DOIs
StatePublished - Jul 16 2018
Externally publishedYes

Fingerprint

Protein Isoforms
Neoplasms
Phosphorylation
Cell Line
Protein Array Analysis
Mutation
Therapeutics

Keywords

  • Activation
  • AKT
  • Expression
  • Isoform
  • Phosphorylation
  • RPPA

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

Wang, J., Zhao, W., Guo, H., Fang, Y., Stockman, S. E., Bai, S., ... Ding, Z. (2018). AKT isoform-specific expression and activation across cancer lineages. BMC Cancer, 18(1), [742]. https://doi.org/10.1186/s12885-018-4654-5

AKT isoform-specific expression and activation across cancer lineages. / Wang, Jue; Zhao, Wei; Guo, Huifang; Fang, Yong; Stockman, Sarah Elizabeth; Bai, Shanshan; Ng, Patrick Kwok Shing; Li, Yang; Yu, Qinghua; Lu, Yiling; Jeong, Kang Jin; Chen, Xiaohua; Gao, Meng; Liang, Jiyong; Li, Wentao; Tian, Xingsong; Jonasch, Eric; Mills, Gordon; Ding, Zhiyong.

In: BMC Cancer, Vol. 18, No. 1, 742, 16.07.2018.

Research output: Contribution to journalArticle

Wang, J, Zhao, W, Guo, H, Fang, Y, Stockman, SE, Bai, S, Ng, PKS, Li, Y, Yu, Q, Lu, Y, Jeong, KJ, Chen, X, Gao, M, Liang, J, Li, W, Tian, X, Jonasch, E, Mills, G & Ding, Z 2018, 'AKT isoform-specific expression and activation across cancer lineages', BMC Cancer, vol. 18, no. 1, 742. https://doi.org/10.1186/s12885-018-4654-5
Wang J, Zhao W, Guo H, Fang Y, Stockman SE, Bai S et al. AKT isoform-specific expression and activation across cancer lineages. BMC Cancer. 2018 Jul 16;18(1). 742. https://doi.org/10.1186/s12885-018-4654-5
Wang, Jue ; Zhao, Wei ; Guo, Huifang ; Fang, Yong ; Stockman, Sarah Elizabeth ; Bai, Shanshan ; Ng, Patrick Kwok Shing ; Li, Yang ; Yu, Qinghua ; Lu, Yiling ; Jeong, Kang Jin ; Chen, Xiaohua ; Gao, Meng ; Liang, Jiyong ; Li, Wentao ; Tian, Xingsong ; Jonasch, Eric ; Mills, Gordon ; Ding, Zhiyong. / AKT isoform-specific expression and activation across cancer lineages. In: BMC Cancer. 2018 ; Vol. 18, No. 1.
@article{2e38d628c554455a8b1bbc78a71939f9,
title = "AKT isoform-specific expression and activation across cancer lineages",
abstract = "Background: Aberrant AKT activation is prevalent across human cancer lineages, providing an important therapeutic target. AKT comprises three isoforms that mediate critical non-redundant, even opposing functions in cancer pathophysiology. Therefore, targeting specific AKT isoforms in particular cancers may be more effective than pan-AKT inhibition while avoiding disadvantages of pan-AKT inhibition. Currently, AKT isoform-specific expression and activation in cancer are not clearly characterized. Methods: We systematically characterized AKT isoform-specific expression and activation in 211 cancer cell lines derived from different lineages and genetic backgrounds using a reverse-phase protein array platform. Results: We found that phosphorylation, but not expression, of AKT1 and AKT2 was coordinated in most but not all cells. Different cancer lineages displayed differential AKT1 and AKT2 expression and phosphorylation. A PIK3CA hotspot mutation H1047R but not E545K was associated with selective activation of AKT2 but not AKT1. Conclusions: Our study identified and validated AKT isoform-specific expression and phosphorylation in certain cell lines and demonstrated that genetic changes can affect AKT isoform-specific activation. These results provide a more precise understanding of AKT isoform-specific signaling and, in addition, facilitate AKT isoform targeting for personalized cancer therapies.",
keywords = "Activation, AKT, Expression, Isoform, Phosphorylation, RPPA",
author = "Jue Wang and Wei Zhao and Huifang Guo and Yong Fang and Stockman, {Sarah Elizabeth} and Shanshan Bai and Ng, {Patrick Kwok Shing} and Yang Li and Qinghua Yu and Yiling Lu and Jeong, {Kang Jin} and Xiaohua Chen and Meng Gao and Jiyong Liang and Wentao Li and Xingsong Tian and Eric Jonasch and Gordon Mills and Zhiyong Ding",
year = "2018",
month = "7",
day = "16",
doi = "10.1186/s12885-018-4654-5",
language = "English (US)",
volume = "18",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - AKT isoform-specific expression and activation across cancer lineages

AU - Wang, Jue

AU - Zhao, Wei

AU - Guo, Huifang

AU - Fang, Yong

AU - Stockman, Sarah Elizabeth

AU - Bai, Shanshan

AU - Ng, Patrick Kwok Shing

AU - Li, Yang

AU - Yu, Qinghua

AU - Lu, Yiling

AU - Jeong, Kang Jin

AU - Chen, Xiaohua

AU - Gao, Meng

AU - Liang, Jiyong

AU - Li, Wentao

AU - Tian, Xingsong

AU - Jonasch, Eric

AU - Mills, Gordon

AU - Ding, Zhiyong

PY - 2018/7/16

Y1 - 2018/7/16

N2 - Background: Aberrant AKT activation is prevalent across human cancer lineages, providing an important therapeutic target. AKT comprises three isoforms that mediate critical non-redundant, even opposing functions in cancer pathophysiology. Therefore, targeting specific AKT isoforms in particular cancers may be more effective than pan-AKT inhibition while avoiding disadvantages of pan-AKT inhibition. Currently, AKT isoform-specific expression and activation in cancer are not clearly characterized. Methods: We systematically characterized AKT isoform-specific expression and activation in 211 cancer cell lines derived from different lineages and genetic backgrounds using a reverse-phase protein array platform. Results: We found that phosphorylation, but not expression, of AKT1 and AKT2 was coordinated in most but not all cells. Different cancer lineages displayed differential AKT1 and AKT2 expression and phosphorylation. A PIK3CA hotspot mutation H1047R but not E545K was associated with selective activation of AKT2 but not AKT1. Conclusions: Our study identified and validated AKT isoform-specific expression and phosphorylation in certain cell lines and demonstrated that genetic changes can affect AKT isoform-specific activation. These results provide a more precise understanding of AKT isoform-specific signaling and, in addition, facilitate AKT isoform targeting for personalized cancer therapies.

AB - Background: Aberrant AKT activation is prevalent across human cancer lineages, providing an important therapeutic target. AKT comprises three isoforms that mediate critical non-redundant, even opposing functions in cancer pathophysiology. Therefore, targeting specific AKT isoforms in particular cancers may be more effective than pan-AKT inhibition while avoiding disadvantages of pan-AKT inhibition. Currently, AKT isoform-specific expression and activation in cancer are not clearly characterized. Methods: We systematically characterized AKT isoform-specific expression and activation in 211 cancer cell lines derived from different lineages and genetic backgrounds using a reverse-phase protein array platform. Results: We found that phosphorylation, but not expression, of AKT1 and AKT2 was coordinated in most but not all cells. Different cancer lineages displayed differential AKT1 and AKT2 expression and phosphorylation. A PIK3CA hotspot mutation H1047R but not E545K was associated with selective activation of AKT2 but not AKT1. Conclusions: Our study identified and validated AKT isoform-specific expression and phosphorylation in certain cell lines and demonstrated that genetic changes can affect AKT isoform-specific activation. These results provide a more precise understanding of AKT isoform-specific signaling and, in addition, facilitate AKT isoform targeting for personalized cancer therapies.

KW - Activation

KW - AKT

KW - Expression

KW - Isoform

KW - Phosphorylation

KW - RPPA

UR - http://www.scopus.com/inward/record.url?scp=85050135548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050135548&partnerID=8YFLogxK

U2 - 10.1186/s12885-018-4654-5

DO - 10.1186/s12885-018-4654-5

M3 - Article

VL - 18

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 742

ER -